BPMC Company Profile and Key Details
NASDAQ : BPMC
Blueprint Medicines
$129.46
0.18+0.14%
At Close 4:00 PMNot Actively Trading
62.9
BESG ScoreESG Rating
Price Chart
Stock Price Today
Blueprint Medicines Corporation (BPMC) stock surged +0.14%, trading at $129.46 on NASDAQ, up from the previous close of $129.28. The stock opened at $129.46, fluctuating between $129.46 and $129.46 in the recent session.
Stock Snapshot
129.28
Prev. Close
8.36B
Market Cap
129.46
Day Low
-51.57768924302789
P/E Ratio
-2.51
EPS (TTM)
-7.44
Cash Flow per Share
129.46
Open
64.58M
Number of Shares
129.46
Day High
92.91%
Free Float in %
2.14
Book Value
2.98M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 17, 2025 | 129.35 | 129.55 | 129.30 | 129.46 | 2.93M |
| Jul 16, 2025 | 129.34 | 129.65 | 129.20 | 129.28 | 25.27M |
| Jul 15, 2025 | 129.33 | 129.40 | 129.31 | 129.35 | 5.12M |
| Jul 14, 2025 | 129.30 | 129.47 | 129.25 | 129.36 | 6.67M |
| Jul 11, 2025 | 129.32 | 129.35 | 129.00 | 129.30 | 3.48M |
| Jul 10, 2025 | 129.49 | 129.49 | 129.23 | 129.33 | 5.98M |
| Jul 09, 2025 | 128.47 | 128.58 | 128.35 | 128.55 | 3M |
| Jul 08, 2025 | 128.37 | 128.78 | 128.31 | 128.40 | 2.96M |
| Jul 07, 2025 | 128.31 | 128.44 | 128.22 | 128.40 | 1.86M |
| Jul 03, 2025 | 128.25 | 128.40 | 128.20 | 128.35 | 1.35M |
| Jul 02, 2025 | 128.35 | 128.45 | 128.20 | 128.20 | 2.28M |
| Jul 01, 2025 | 128.18 | 128.52 | 128.16 | 128.34 | 2.59M |
| Jun 30, 2025 | 128.30 | 128.32 | 128.08 | 128.18 | 2.35M |
| Jun 27, 2025 | 128.24 | 128.28 | 128.06 | 128.11 | 2.8M |
| Jun 26, 2025 | 128.29 | 128.31 | 128.10 | 128.15 | 2.47M |
| Jun 25, 2025 | 128.30 | 128.32 | 128.19 | 128.25 | 2.44M |
| Jun 24, 2025 | 128.40 | 128.40 | 128.15 | 128.26 | 3.38M |
| Jun 23, 2025 | 128.19 | 128.45 | 128.11 | 128.40 | 3.41M |
| Jun 20, 2025 | 128.27 | 128.30 | 128.00 | 128.20 | 4.49M |
| Jun 18, 2025 | 128.29 | 128.32 | 128.02 | 128.12 | 3.48M |
Contact Details
About Company
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 682 |
| Beta | 0.83 |
| Sales or Revenue | $249.38M |
| 5Y Sales Change% | 3.058% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
-24.1-3.05%
Regeneron Pharmaceuticals, Inc.$766.66ARGX-8.04-1.06%
argenx SE$748.72UTHR-15.17-2.95%
United Therapeutics Corporation$498.65VRTX-11.76-2.42%
Vertex Pharmaceuticals Incorporated$474.27MDGL-9.77-2.24%
Madrigal Pharmaceuticals, Inc.$425.85KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-6.42-1.97%
Alnylam Pharmaceuticals, Inc.$318.65PRAX-12.37-3.74%
Praxis Precision Medicines, Inc.$318.22KRYS4.99+1.93%
Krystal Biotech, Inc.$263.80ASND-2.87-1.19%
Ascendis Pharma A/S$239.22Company Overview
Blueprint Medicines Corporation (NASDAQ:BPMC) closed at $129.46 USD, gaining $0.18 (0.14%) from the previous close of $129.28. The stock is currently trading near its 52-week high $73.04 and $129.55. With a market capitalization of about $8.36 billion, Blueprint Medicines Corporation is classified as a mid-cap and shows market-like volatility (beta ~0.83). Key stats such as the average daily volume over the past year has been around 3.29 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Blueprint Medicines Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kathryn Haviland, the company employs approximately 682 people and listed since April 30, 2015. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 0.67%, SMA50 9.56%, SMA200 30.2%). The stock’s 14-day RSI is 76.66 (overbought), while the ATR of 0.85 points to tighter daily ranges. The stock remains sitting in the mid-range of its 52-week band, trading -0.15% below its high and over 77.25% above its low.
Valuation Metrics
Blueprint Medicines Corporation trades at a P/E ratio of -77.87, slightly below the S&P 500 average, with a price-to-sales ratio of 19.72 and a price-to-book ratio of 24.07 reflecting a rich premium to book value. The P/FCF stands at -83.38, also above market averages. Compared to sector medians, Blueprint Medicines Corporation P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.
Dividend & Fair Value
Blueprint Medicines Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $46.94. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
Blueprint Medicines Corporation generated EPS of -$2.46 over the past year. Five-year average earnings growth is 31.87%. The latest quarter delivered EPS of -$0.74. The next quarter is forecast at -$0.47. Next year's EPS is expected at $34.45. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $150.00 to $100.00. The high target offers 15.87% upside. The low target suggests -22.76% downside. The mean target is $130.00. This offers 0.42% upside. Blueprint Medicines Corporation earnings surprise history is a mixed track record. The quarter that ended May 01, 2025, missed forecasts by 76.19%. The prior quarter beat by 16.18%. Over the last six quarters, Apple has recorded several small beats. These include -10.78% in February 15, 2024.
Shareholding & Insider Activity
Blueprint Medicines Corporation has 64.58 million shares outstanding. The public float is 60.00 million shares, elevated short interest at 5.45% of float. This equals 3.13 million shares. The short ratio is 0.62 days. Institutional investors hold 110.85% of the float. Insiders own 0.87%. Haviland Kate holds 165.93 thousand shares, Albers Jeffrey W. has 146.63 thousand shares and Namouni Fouad has 75.78 thousand shares.
Financial & Profitability Overview
On valuation metrics, Blueprint Medicines trades at a P/E of -77.87, P/S of 19.72 and P/B of 24.07. The current ratio is 2.80 and quick ratio is 2.75. Operationally, the company’s inventory turnover is 0.94 and cash conversion cycle is 432.86 days. Debt-to-equity is 0.36, supported by a cash flow-to-debt ratio of -0.79.
Quarterly Financial Highlights
The company ended the quarter with $710.64M in cash and short-term investments, a total debt of $774.12M, and net debt of $702.84M. Total assets were $1.05B, with equity of $130.61M. Financials further reflected weakness, with operating cash flow of - $436.85M, free cash flow of - $452.91M, and capital expenditures of - $16.06M.
Frequently Asked Questions
What is the current Blueprint Medicines Corporation (BPMC) stock price?
Blueprint Medicines Corporation (NASDAQ: BPMC) stock price is $129.46 in the last trading session. During the trading session, BPMC stock reached the peak price of $129.46 while $129.46 was the lowest point it dropped to. The percentage change in BPMC stock occurred in the recent session was 0.14% while the dollar amount for the price change in BPMC stock was $0.18.
BPMC's industry and sector of operation?
The NASDAQ listed BPMC is part of Biotechnology industry that operates in the broader Healthcare sector. Blueprint Medicines Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BPMC?
Ms. Debra Durso-Bumpus
Chief People Officer
Dr. Percy H. Carter M.B.A., Ph.D.
Chief Scientific Officer
Jenna Cohen
Senior Director & Head of Investor Relations
Mr. Michael Landsittel
Chief Financial Officer
Mr. Alexis A. Borisy A.M.
Founder & Executive Chairman of Board of Directors
Ms. Tracey L. McCain Esq.
Executive Vice President, Chief Legal & Compliance Officer and Sec.
Mr. Jeffrey W. Albers J.D., M.B.A., MBA
Executive Chairman
Ms. Christina Rossi
Chief Operating Officer
Dr. Christopher K. Murray
Senior Vice President of Technical Operations
Dr. Christopher K. Murray Ph.D.
Senior Vice President of Technical Operations and Chief Technical Operations & Quality Officer
Ms. Ariel Hurley
Senior Vice President, Fin. & Principal Accounting Officer
Ms. Kathryn Haviland
Pres, Chief Executive Officer & Director
Chief People Officer
Dr. Percy H. Carter M.B.A., Ph.D.
Chief Scientific Officer
Jenna Cohen
Senior Director & Head of Investor Relations
Mr. Michael Landsittel
Chief Financial Officer
Mr. Alexis A. Borisy A.M.
Founder & Executive Chairman of Board of Directors
Ms. Tracey L. McCain Esq.
Executive Vice President, Chief Legal & Compliance Officer and Sec.
Mr. Jeffrey W. Albers J.D., M.B.A., MBA
Executive Chairman
Ms. Christina Rossi
Chief Operating Officer
Dr. Christopher K. Murray
Senior Vice President of Technical Operations
Dr. Christopher K. Murray Ph.D.
Senior Vice President of Technical Operations and Chief Technical Operations & Quality Officer
Ms. Ariel Hurley
Senior Vice President, Fin. & Principal Accounting Officer
Ms. Kathryn Haviland
Pres, Chief Executive Officer & Director
How BPMC did perform over past 52-week?
BPMC's closing price is 77.25% higher than its 52-week low of $73.04 where as its distance from 52-week high of $129.55 is -0.07%.
How many employees does BPMC have?
Number of BPMC employees currently stands at 682.
Link for BPMC official website?
Official Website of BPMC is: https://www.blueprintmedicines.com
How do I contact BPMC?
BPMC could be contacted at phone 617 374 7580 and can also be accessed through its website. BPMC operates from 45 Sidney Street, Cambridge, MA 02139, United States.
How many shares of BPMC are traded daily?
BPMC stock volume for the day was 2.98M shares. The average number of BPMC shares traded daily for last 3 months was 3.29M.
What is the market cap of BPMC currently?
The market value of BPMC currently stands at $8.36B with its latest stock price at $129.46 and 64.58M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep